Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04834752 Not yet recruiting - COVID-19 Clinical Trials

Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19

Start date: May 1, 2021
Phase:
Study type: Observational

This retrospective cohort study aims to evaluate the effect of proton pump inhibitor (PPI) or histamine-2 receptor antagonist (H2RA) on the clinical outcomes and positivity rates of Coronavirus Disease-19 (COVID-19).

NCT ID: NCT04834739 Completed - Covid19 Clinical Trials

Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19

Start date: January 4, 2021
Phase: N/A
Study type: Interventional

This study aimed to investigate if the functional capacity of health workers sustained covid 19 infection effects functional capacity , quality of life and mood of health workers when comparing healthy health workers.

NCT ID: NCT04834726 Completed - Covid19 Clinical Trials

COVID-19 Vaccine Text Outreach

Start date: April 29, 2021
Phase: N/A
Study type: Interventional

This project aims to evaluate different approaches to increase COVID-19 vaccine uptake among at-risk patients at Penn Medicine in an equitable and systematic manner through a centralized outreach program. The investigators will evaluate different text-based scheduling and messaging approaches informed by behavioral science to increase uptake among eligible patients, including the use of clinician endorsement, opt-out framing, and scarcity.

NCT ID: NCT04834583 Completed - Covid19 Clinical Trials

Corona And Manual Professions

CAMP
Start date: November 2, 2020
Phase:
Study type: Observational

This observational study will follow the chiropractors and naprapaths in Sweden to study how work environment, health, and economy is changing during the COVID-19 pandemic.

NCT ID: NCT04834401 Completed - Multiple Sclerosis Clinical Trials

Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis

Start date: March 22, 2021
Phase:
Study type: Observational

This observational study is intended to evaluate the effect of disease modifying therapies on antibody responses to the mRNA-1273 vaccine (Moderna) for COVID-19. We hypothesize that the use of certain disease modifying therapies, particularly ocrelizumab, will mute and/or shorten the duration of humoral response to mRNA vaccines.

NCT ID: NCT04834375 Completed - Covid19 Clinical Trials

Randomized Open Investigation Determining Steroid Dose

ROIDS-Dose
Start date: March 19, 2021
Phase: Phase 3
Study type: Interventional

Dexamethasone has been approved for the treatment of severe COVID-19, but higher doses of steroids may be more effective. The purpose of this research study is to compare the current standard dose of dexamethasone 6 mg to a higher, weight-based dosing (0.2 mg/kg with maximum dose of 20 mg) to determine if it would be more effective against COVID-19 pneumonia.

NCT ID: NCT04834128 Withdrawn - COVID - 19 Clinical Trials

A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19

Start date: December 13, 2021
Phase: Phase 2
Study type: Interventional

A Phase II safety and tolerability study of expanded gamma delta T cell lymphocytes (TCB008) in patients diagnosed with COVID-19.

NCT ID: NCT04834115 Recruiting - Covid19 Clinical Trials

Efficacy of Ivermectin in Outpatients With Non-severe COVID-19

Start date: November 17, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized controlled trial to evaluate the efficacy of ivermectin in reducing the risk of progression to severe disease and hospitalizations in COVID-19 patients.

NCT ID: NCT04834102 Recruiting - Covid19 Clinical Trials

COVID-19 Induced Telogen Effluvium

Start date: January 27, 2021
Phase:
Study type: Observational

This study inquires about the development of Telogen effluvium following the SARS-CoV-2 infection

NCT ID: NCT04834089 Not yet recruiting - Cancer Clinical Trials

Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases

SOROCOV
Start date: May 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II Randomized Clinical Trial to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 hyperimmune serum. The study will include patients at early stage of COVID-19 with increased risk for severe disease due to underlying medical conditions to determine the utility of an equine heterologous serum anti-SARS-CoV-2 to avoid progression to a severe COVID-19